scott cadger, head of underwriting and claims strategy at scottish widows, said the industry needed to do more to educate the public on the merits of protection insurance.
.
it's not clear how well they'll stack up against current migraine therapies, because head-to-head studies haven't been done.
.
people who want to learn about and take action on the world�s biggest challenges. extreme poverty ends with you.
.
.
.
.
.
.
eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention.
.